Moleculin Announces Pricing of up to $16.5 Million Public Offering
$5.5 million financing upfront with up to an additional $11.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HOUSTON, Aug. 16, 2024 /PRNewswire-PRWeb/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the...
Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Positive outcome from End of Phase 1B/2 Meeting with FDA - Company proceeding with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for the treatment of R/R AML -...
Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET
HOUSTON, Aug. 5, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it will host a...
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial
Based on an encouraging discussion in the End of Phase 1B/2 Meeting with FDA the Company plans to: Proceed with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for...
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
HOUSTON, July 10, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the completion of its End of...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
- 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations - Current median durability of response (mDOR) of CRc's = 6 months and increasing (n=9) - In 2nd line subjects (n=10) Annamycin in combination with Cytarabine (AnnAraC) achieved an...
Moleculin to Present at the Virtual Investor Pitch Conference
Live video webcast on Tuesday, June 18th at 3:00 PM ET HOUSTON, June 12, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors...
Moleculin to Participate in the Virtual Investor Lunch Break Series
Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Wednesday, June 12th at 12:00 PM ET HOUSTON, June 5, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of...
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
HOUSTON, May 16, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced its abstract has been...
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
- Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin - Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models...